|
gptkbp:instanceOf
|
gptkb:chemical_compound
antineoplastic agent
|
|
gptkbp:administeredBy
|
intravenous infusion
|
|
gptkbp:antidote_for_toxicity
|
mesna
|
|
gptkbp:approvalYear
|
1988
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
L01AA06
|
|
gptkbp:CASNumber
|
3778-73-2
|
|
gptkbp:category
|
prodrug
nitrogen mustard
World Health Organization essential medicine
cytotoxic drug
|
|
gptkbp:chemicalFormula
|
C7H15Cl2N2O2P
|
|
gptkbp:developedBy
|
ASTA Medica
|
|
gptkbp:discoveredBy
|
gptkb:Norbert_Brock
|
|
gptkbp:excretion
|
gptkb:kidney
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Ifosfamide
|
|
gptkbp:IUPACName
|
3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
|
|
gptkbp:KEGGID
|
D00459
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:MeSH_ID
|
D007001
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
261.09 g/mol
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1423
3700
DB01181
|
|
gptkbp:relatedTo
|
gptkb:cyclophosphamide
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
gptkb:encephalopathy
nausea
vomiting
immunosuppression
alopecia
neurotoxicity
myelosuppression
hemorrhagic cystitis
electrolyte imbalance
renal toxicity
|
|
gptkbp:UNII
|
UMF464Q4EG
|
|
gptkbp:usedFor
|
gptkb:cancer
gptkb:rhabdomyosarcoma
leukemia
testicular cancer
|
|
gptkbp:bfsParent
|
gptkb:Asta_Medica
|
|
gptkbp:bfsLayer
|
7
|